These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
218 related articles for article (PubMed ID: 11795386)
1. The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Wolmark N; Dunn BK Ann N Y Acad Sci; 2001 Dec; 949():99-108. PubMed ID: 11795386 [TBL] [Abstract][Full Text] [Related]
2. From adjuvant therapy to breast cancer prevention: BCPT and STAR. Dunn BK; Ford LG Breast J; 2001; 7(3):144-57. PubMed ID: 11469927 [TBL] [Abstract][Full Text] [Related]
3. Chemoprevention for high-risk women: tamoxifen and beyond. Fabian CJ; Kimler BF Breast J; 2001; 7(5):311-20. PubMed ID: 11906441 [TBL] [Abstract][Full Text] [Related]
4. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. Vogel VG; Costantino JP; Wickerham DL; McCaskill-Stevens W; Clarfeld RB; Grant MD; Wolmark N J Natl Cancer Inst Monogr; 2010; 2010(41):181-6. PubMed ID: 20956826 [TBL] [Abstract][Full Text] [Related]
5. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. Vogel VG; Costantino JP; Wickerham DL; Cronin WM Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506 [TBL] [Abstract][Full Text] [Related]
6. Chemoprevention of breast cancer in the older patient. Minton SE Hematol Oncol Clin North Am; 2000 Feb; 14(1):113-30. PubMed ID: 10680075 [TBL] [Abstract][Full Text] [Related]
7. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Vogel VG; Costantino JP; Wickerham DL; Cronin WM; Cecchini RS; Atkins JN; Bevers TB; Fehrenbacher L; Pajon ER; Wade JL; Robidoux A; Margolese RG; James J; Lippman SM; Runowicz CD; Ganz PA; Reis SE; McCaskill-Stevens W; Ford LG; Jordan VC; Wolmark N; JAMA; 2006 Jun; 295(23):2727-41. PubMed ID: 16754727 [TBL] [Abstract][Full Text] [Related]
8. Breast cancer prevention with selective estrogen receptor modulators: a perspective. Pritchard KI Ann N Y Acad Sci; 2001 Dec; 949():89-98. PubMed ID: 11795385 [TBL] [Abstract][Full Text] [Related]
9. Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts. Vogel VG Clin Cancer Res; 2001 Dec; 7(12 Suppl):4413s-4418s; discussion 4411s-4412s. PubMed ID: 11916233 [TBL] [Abstract][Full Text] [Related]
10. The use of tamoxifen and raloxifene for the prevention of breast cancer. Wickerham DL; Costantino JP; Vogel VG; Cronin WM; Cecchini RS; Ford LG; Wolmark N Recent Results Cancer Res; 2009; 181():113-9. PubMed ID: 19213563 [TBL] [Abstract][Full Text] [Related]
11. Chemoprevention of breast cancer. Thomsen A; Kolesar JM Am J Health Syst Pharm; 2008 Dec; 65(23):2221-8. PubMed ID: 19020189 [TBL] [Abstract][Full Text] [Related]
12. Tamoxifen--an update on current data and where it can now be used. Wickerham L Breast Cancer Res Treat; 2002 Oct; 75 Suppl 1():S7-12; discussion S33-5. PubMed ID: 12353826 [TBL] [Abstract][Full Text] [Related]
13. Systematic review: comparative effectiveness of medications to reduce risk for primary breast cancer. Nelson HD; Fu R; Griffin JC; Nygren P; Smith ME; Humphrey L Ann Intern Med; 2009 Nov; 151(10):703-15, W-226-35. PubMed ID: 19920271 [TBL] [Abstract][Full Text] [Related]
14. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Fisher B; Costantino JP; Wickerham DL; Redmond CK; Kavanah M; Cronin WM; Vogel V; Robidoux A; Dimitrov N; Atkins J; Daly M; Wieand S; Tan-Chiu E; Ford L; Wolmark N J Natl Cancer Inst; 1998 Sep; 90(18):1371-88. PubMed ID: 9747868 [TBL] [Abstract][Full Text] [Related]
15. National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities. McCaskill-Stevens W; Wilson JW; Cook ED; Edwards CL; Gibson RV; McElwain DL; Figueroa-Moseley CD; Paskett ED; Roberson NL; Wickerham DL; Wolmark N Clin Trials; 2013 Apr; 10(2):280-91. PubMed ID: 23335675 [TBL] [Abstract][Full Text] [Related]
16. The effect of SERMs on the endometrium. Goldstein SR Ann N Y Acad Sci; 2001 Dec; 949():237-42. PubMed ID: 11795358 [TBL] [Abstract][Full Text] [Related]
17. Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Levine M; Moutquin JM; Walton R; Feightner J; CMAJ; 2001 Jun; 164(12):1681-90. PubMed ID: 11450210 [TBL] [Abstract][Full Text] [Related]
18. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728 [TBL] [Abstract][Full Text] [Related]
19. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. Fisher B; Costantino JP; Redmond CK; Fisher ER; Wickerham DL; Cronin WM J Natl Cancer Inst; 1994 Apr; 86(7):527-37. PubMed ID: 8133536 [TBL] [Abstract][Full Text] [Related]